ICU · Obstetric / pharmacotherapy
ICU Drugs in Pregnancy & Lactation — Safe, Caution & Contraindicated
Also known as Teratogenicity · Drugs in pregnancy · Drugs in lactation · FDA pregnancy categories · PLLR · ACE fetopathy · Fetal warfarin syndrome · Labetalol · LMWH in pregnancy · Pregnancy labelling rule · LactMed · Relative infant dose · Fetal valproate syndrome · Retinoid embryopathy
The ICU drugs in pregnancy: the PLACENTA crosses MOST drugs (the trimester matters — the organogenesis weeks 3 to 10 the highest the teratogenic risk). The SAFE: LMWH (does NOT cross placenta), labetalol (the first-line antihypertensive), penicillins, cephalosporins, macrolides, propofol, noradrenaline, steroids (prednisolone — the 90 per cent metabolised by the placental 11-beta-HSD2), paracetamol, insulin, metformin, magnesium. The CAUTION: aminoglycosides (fetal ototoxicity), benzodiazepines (1st trimester), fluoroquinolones. The CONTRAINDICATED: warfarin (the fetal warfarin syndrome), ACE inhibitors and ARBs (ACE fetopathy — fetal renal damage), valproate (neural tube), isotretinoin, methotrexate, tetracyclines (teeth/bone), lithium. The LACTATION: most ICU drugs compatible (infant dose under 1 per cent); avoid chloramphenicol, amiodarone, lithium, chemotherapy, radioisotopes — check LactMed.
On this page & tools
Your progress
Saved locally on this device.
8 MCQs with explanations
Target exams
Red flags
Overview & definition
The ICU drugs in pregnancy — the placenta crosses MOST drugs. The trimester matters (the organogenesis weeks 3 to 10 the highest the teratogenic risk). The two principles: (1) the know the safe, the caution, and the contraindicated, and (2) the treat the mother FIRST (the maternal the survival the paramount — the a dead mother the a dead fetus).[1]
The critical-care prescriber's job in pregnancy distils to four questions on every drug chart: (1) Is this drug on the contraindicated list? (2) Does the indication outweigh any residual fetal risk? (3) Is the mother getting adequate, undiluted treatment — am I under-dosing her out of fetal fear? (4) If she is breastfeeding, is the drug compatible, or do I pump-and-dump? The cardinal error is to withhold effective maternal therapy (vasopressors, anticoagulation, antibiotics, antiepileptics) for speculative fetal concern — maternal hypotension, hypoxia, sepsis, seizures and thrombosis each kill the fetus far more reliably than any sensibly chosen drug.[1][1]
FDA pregnancy categories: the legacy A/B/C/D/X system
From 1979 to 2015 the FDA labelled every drug with a single letter category (A → X) summarising fetal risk. This was replaced in 2015 by the Pregnancy and Lactation Labelling Rule (PLLR) — narrative labelling replacing the letter. The letters are gone from US inserts but still dominate exams, textbooks and clinical memory, so you must know both.[1][1]
FDA pregnancy categories (legacy A–X) — definitions and examples
| Category | Definition | Examples (exam-classic) |
|---|---|---|
| A | Adequate, well-controlled human studies — NO fetal risk in any trimester | Levothyroxine, folic acid, vitamin/minerals (pregnancy doses), magnesium sulfate, potassium chloride |
| B | Animal studies show NO risk; no adequate human studies OR animal toxicity but controlled human studies show NO risk | Penicillins, cephalosporins, macrolides (azithromycin), metformin, insulin, heparin/LMWH, acetaminophen (paracetamol), ondansetron, ranitidine-family, methyldopa, propofol, ketamine, phenylephrine |
| C | Animal studies show adverse effect OR no studies; use only if benefit justifies risk — MOST drugs sit here | Noradrenaline (norepinephrine), adrenaline (epinephrine), fluconazole, vancomycin, clarithromycin, gentamicin/aminoglycosides (traditionally C, often reclassified — see caution), prednisolone, midazolam, fentanyl, morphine, propafenone, amiodarone (X late pregnancy — see below) |
| D | Positive evidence of human fetal risk, BUT benefits may be acceptable (life-threatening illness, no safer drug) | Phenytoin, carbamazepine, phenobarbital, valproate (often classified X), tetracyclines, aminoglycosides (some references), benzodiazepines (3rd trimester), lithium, spironolactone, NSAIDs (3rd trimester) |
| X | Positive evidence of fetal abnormalities; risk CLEARLY outweighs benefit — CONTRAINDICATED | Warfarin, isotretinoin/etretinate, methotrexate, misoprostol (for abortion; other uses differ), thalidomide, diethylstilboestrol, leflunomide, lovastatin/simvastatin, oral contraceptives (high-dose) |
Why the letters were abandoned (the PLLR, 2015). A single letter could not capture (a) the strong trimester dependence of risk (e.g. NSAIDs are fine mid-pregnancy but constrict the fetal ductus arteriosus and oligohydramnios after ~20 weeks; warfarin is teratogenic 6–12 weeks but haemorrhagic throughout); (b) the dose–response (low-dose aspirin is protective, high-dose salicylates are teratogenic); (c) the distinction between "no data" (C) and "known harm" (D/X), which are clinically very different. The PLLR mandates three structured narrative subsections — 8.1 Pregnancy (risk summary, clinical considerations, data), 8.2 Lactation (risk summary, data), and 8.3 Females/Males of Reproductive Potential.[1]
The practical upshot for the intensivist: letter categories are a memory scaffold, not a prescribing tool. When a drug is unfamiliar, read the PLLR narrative or consult Briggs' Drugs in Pregnancy and Lactation (the reference standard) and the LactMed database.[1][1]
Teratogenesis — timing, mechanism, dose
Teratogenesis is not an on/off switch; it is timing × dose × genetic susceptibility. The embryonic period — weeks 3–8 post-conception (i.e. weeks 5–10 from last menstrual period) — is the window of organogenesis, when the major organs are being formed cell-by-cell. A teratogen in this window produces structural malformations (the classic teratogenic syndromes — fetal warfarin, retinoid embryopathy, neural tube defects). Before week 3 the "all-or-none" rule applies: the embryo is a few cells — a toxin either kills it outright or the survivors regenerate a whole embryo (no malformation). After week 10, organogenesis is largely complete and teratogens instead cause growth restriction, functional deficits and organ-specific toxicity (e.g. ACE fetopathy is a 2nd/3rd-trimester phenomenon — fetal kidney is formed but the drug causes oligohydramnios and renal failure; tetracyclines discolour forming teeth/bone throughout).[1]
Mechanisms of teratogenesis — the five ways a drug harms the fetus
- STRUCTURAL MALFORMATION (organogenesis window, weeks 3–10) — The classic teratogens: warfarin → nasal hypoplasia, stippled epiphyses; isotretinoin → craniofacial, cardiac, thymic, CNS defects (retinoic acid signalling drives neural-crest migration); valproate → neural tube (inhibits folate, histone deacetylase inhibition); methotrexate → antifolate effects (skeletal, CNS). Mechanisms: altered cell migration, proliferation, apoptosis.
- ORGAN-SPECIFIC TOXICITY (any trimester) — Aminoglycosides → fetal cochlear hair-cell destruction (ototoxicity, usually high-dose/prolonged); ACE inhibitors/ARBs → fetal renal artery vasoconstriction → oligohydramnios, renal failure, cranial ossification defects (2nd/3rd trimester); tetracyclines → chelate calcium in forming teeth and bone → brown discoloration, enamel hypoplasia, growth inhibition.
- HAEMODYNAMIC / PLACENTAL EFFECTS — NSAIDs and COX-2 inhibitors → constriction of the ductus arteriosus (after ~20 weeks) → fetal pulmonary hypertension, oligohydramnios (reduced fetal urine); vasoconstrictors (high-dose) → reduced uteroplacental perfusion; the same logic applies to maternal hypotension — anything that drops uterine blood flow (shock, over-treatment with vasodilators) causes fetal hypoxia.
- NEURODEVELOPMENTAL / COGNITIVE DEFICITS (any trimester, often late) — Antiepileptics (valproate worst — NEAD trial: 6-year-old children exposed to valproate had IQ 6–9 points lower); benzodiazepines (chronic 3rd-trimester use → "floppy infant," withdrawal); alcohol (fetal alcohol spectrum disorder — the most common preventable cause of intellectual disability).
- NEONATAL WITHDRAWAL / ADAPTATION SYNDROME (near term) — Opioids (methadone, morphine, fentanyl infusion), SSRIs (serotonin discontinuation), benzodiazepines, gabapentin — neonatal abstinence syndrome within 24–72 h of birth. Not a malformation but a real ICU-relevant consequence of late-pregnancy exposure.
Dose and route matter. Topical, inhaled and minimal-absorption drugs (inhaled salbutamol, topical steroids, oral nystatin, sucralfate) achieve negligible maternal serum levels and are therefore low-risk regardless of category. The concern rises with systemic, sustained, high-dose exposure (e.g. pulse high-dose steroids, IV bisphosphonates, chemotherapy).[1]
The safe drugs in pregnancy
Anticoagulants
- The LMWH (enoxaparin) — SAFE (does NOT cross the placenta — the large the molecule). The preferred for the VTE prophylaxis and treatment in pregnancy.[1]
- The UFH — SAFE (does NOT cross the placenta).[1]
- The warfarin — CONTRAINDICATED (the fetal warfarin syndrome — the nasal hypoplasia, the stippled epiphyses, the CNS abnormalities, the fetal haemorrhage).[1]
- The DOACs — the insufficient the data; AVOID.[1]
Fondaparinux also does not cross the placenta and is a safe option in heparin-allergic (HIT) pregnant patients. The ASH 2018 guideline recommends LMWH over UFH for both treatment and prophylaxis of pregnancy-associated VTE, dosed weight-based (enoxaparin 1 mg/kg bd for treatment; 40 mg daily or 0.5 mg/kg daily for prophylaxis) and switched to UFH infusion ~36 h before planned delivery to permit neuraxial anaesthesia.[1]
Antihypertensives
- The labetalol — the first-line (the beta-blocker; the safe).[1]
- The hydralazine, the methyldopa, the nifedipine — SAFE.[1]
- The ACE inhibitors and the ARBs — CONTRAINDICATED (the ACE fetopathy — the fetal renal damage, the oligohydramnios, the cranial ossification defects, the fetal death).[1]
Methyldopa is the drug with the longest pregnancy safety record (decades of follow-up data, no teratogenicity, no long-term neurodevelopmental harm at 7-year follow-up) but is centrally sedating and too slow for an ICU hypertensive emergency. Nifedipine (dihydropyridine CCB) is safe and oral; avoid co-administering nifedipine with IV magnesium (severe hypotension, neuromuscular blockade reported). Avoid nitroprusside (fetal cyanide/thiocyanate), diuretics as first-line (contract the already-low pregnancy plasma volume → reduce placental perfusion), and atenolol in early pregnancy (associated with fetal growth restriction).[1]
Antibiotics
- The penicillins, the cephalosporins, the macrolides (azithromycin), the vancomycin, the clindamycin, the metronidazole (the 2nd and 3rd trimester) — SAFE.[1]
- The aminoglycosides — the CAUTION (the fetal the ototoxicity; the use the if the essential).[1]
- The tetracyclines — CONTRAINDICATED (the teeth the discoloration, the bone the effects).[1]
- The trimethoprim — the CAUTION the 1st trimester (the neural tube).[1]
Penicillins and cephalosporins are the backbone of obstetric sepsis therapy — no teratogenicity across all trimesters, and the increased renal clearance and expanded volume of distribution in pregnancy means you often need higher and more frequent dosing (e.g. ceftriaxone 2 g bd rather than once daily) to achieve sepsis-appropriate serum levels. Nitrofurantoin is safe for cystitis in pregnancy EXCEPT avoid at term (G6PD-related neonatal haemolysis). Fluoroquinolones (ciprofloxacin) damage immature cartilage in animal models — avoid unless no alternative (severe resistant infection). Chloramphenicol causes grey-baby syndrome (immature glucuronidation) — avoid at term. Linezolid and meropenem have limited data but are used in life-threatening resistant infection.[1]
Analgesia and antipyretics
- Paracetamol (acetaminophen) — SAFE; first-line analgesic and antipyretic throughout pregnancy (oral 1 g qid or IV 1 g). Reassuring human data; recent cohort signals of possible fetal urogenital/behavioural effects with sustained high-dose use have NOT changed first-line status. Avoid chronic maximum dosing.
- Fentanyl, morphine, oxycodone — SAFE as single doses/short courses; near-term chronic use → neonatal abstinence syndrome (see below).
- NSAIDs (ibuprofen, diclofenac, indomethacin, ketorolac) — AVOID after 20 weeks (FDA 2020 warning: oligohydramnios from fetal renal effects; also ductus arteriosus constriction → pulmonary hypertension). Before 20 weeks short courses are acceptable; indomethacin is still used short-term by obstetrics for tocolysis with fetal cardiac monitoring.
- Aspirin — LOW-DOSE (75–150 mg) SAFE and recommended for pre-eclampsia prophylaxis in high-risk women from 12 weeks; HIGH-DOSE aspirin and full-dose NSAIDs AVOID (bleeding, premature ductal closure). [1]
Antidiabetics
- Insulin — SAFE; the drug of choice for gestational and pre-existing diabetes in pregnancy. Does NOT cross the placenta (large peptide). Titrate to target fasting glucose <5.3 mmol/L and 1-h postprandial <7.8 mmol/L.
- Metformin — SAFE (Category B); does not cross placenta significantly; large randomised data (MIG trial) show no short-term harm and is used for gestational diabetes and PCOS. Reassuring but long-term offspring data still maturing.
- Sulfonylureas — glibenclamide (glyburide) historically used; less preferred than insulin. AVOID the newer agents with pregnancy data gaps: SGLT2 inhibitors (dapagliflozin), GLP-1 agonists (semaglutide), DPP-4 inhibitors — stop before/once pregnancy confirmed.
- Statins — traditionally contraindicated (Category X for simvastatin/lovastatin); the data is now considered weak and statins are being studied in pre-eclampsia prevention, but still routinely discontinued in pregnancy until clearer evidence. [1]
Sedation and analgesia
- The propofol — SAFE.[1]
- The fentanyl, the morphine — SAFE (the neonatal withdrawal if the near the term).[1]
- The ketamine — SAFE.[1]
- The benzodiazepines — the CAUTION the 1st trimester (the cleft the palate — the controversial; the midazolam the OK for the short-term).[1]
For prolonged ICU sedation in a pregnant patient, propofol ± fentanyl is the workhorse. Avoid nitrous oxide in the first trimester (theoretical folate/teratogenic concern) and avoid prolonged high-dose benzodiazepines (withdrawal). Dexmedetomidine has reassuring animal data and is used; human data remains limited but no teratogenic signal. [1]
Vasopressors
- The noradrenaline — the PREFERRED (the minimal the placental transfer).[1]
- The phenylephrine, the vasopressin — SAFE.[1]
- The adrenaline — the CAUTION (the uterine the vasoconstriction; the reduce the uteroplacental the perfusion).[1]
(See the dedicated vasopressor section below — the overriding principle is that maternal hypotension is worse than any single vasopressor.) [1]
Steroids
- The prednisolone — SAFE (the 90 per cent metabolised by the placental 11-beta-HSD2; the minimal the fetal the exposure).[1]
- The dexamethasone and the betamethasone — the CROSS the placenta (the used for the fetal the lung the maturation — the NOT the metabolised by the 11-beta-HSD2).[1]
This is a high-yield exam point: prednisolone is placenta-metabolised (fetal exposure low) while betamethasone/dexamethasone cross to the fetus (intended — for lung maturation). Hydrocortisone crosses partially. Use betamethasone or dexamethasone (24 mg in divided doses over 24 h, two doses) for fetal lung maturation between 24–34 weeks when preterm delivery threatened.[1]
Antiepileptics
- The levetiracetam — the SAFEST.[1]
- The valproate — CONTRAINDICATED (the neural tube defects — the #1 the teratogenic the AED).[1]
In status epilepticus in pregnancy, levetiracetam and the benzodiazepines (lorazepam) are the first-line agents. Phenytoin and carbamazepine (older AEDs) carry fetal risk (facial clefts, cardiac defects, neural tube — Jentink 2010) and are second-line; valproate is the worst (1st-trimester neural tube defects + the worst cognitive outcome on the NEAD trial — avoid if any alternative exists). Lamotrigine has the most reassuring safety profile of the maintenance AEDs.[1][1]
Teratogenic drugs to AVOID — the dangerous handful
This is the must-know list for every ICU exam and every pregnant admission. Each drug has a recognisable fetal syndrome and a safe substitute. [1]
The contraindicated-in-pregnancy drugs — syndrome and safe substitute
| Drug (class) | Fetal syndrome / harm | Critical window | Safe substitute |
|---|---|---|---|
| Warfarin | Fetal warfarin syndrome — nasal hypoplasia, stippled epiphyses, optic atrophy, CNS (Dandy-Walker, agenesis corpus callosum), fetal/intracranial haemorrhage | 6–12 wks (teratogenic); throughout (haemorrhagic, esp. around delivery) | LMWH / UFH (do not cross placenta) |
| ACE inhibitors / ARBs | ACE fetopathy — fetal renal failure → oligohydramnios, limb contractures (Potter sequence), cranial ossification defects, hypocalvaria, IUGR, fetal death | 2nd/3rd trimester (severe); 1st trimester now also avoided (Cooper 2006 — malformations) | Labetalol, methyldopa, hydralazine, nifedipine |
| Valproate | Fetal valproate syndrome — neural tube defects, cardiac, facial, limb; worst IQ impact of any AED (NEAD trial) | 1st trimester (structural); throughout (cognitive) | Levetiracetam, lamotrigine, carbamazepine (if AED essential) |
| Isotretinoin / etretinate / acitretin (oral retinoids) | Retinoic acid embryopathy — craniofacial, cardiac (conotruncal), thymic aplasia, CNS; ~20–35% affected | Anytime in pregnancy (acitretin avoid pregnancy for 3 yr after) | Topical agents; defer systemic retinoids; iPLEDGE contraception programme |
| Methotrexate (low dose, weekly) | Aminopterin/methotrexate syndrome — cranial, limb, CNS; a classic abortifacient | 1st trimester | Switch to azathioprine / sulfasalazine / hydroxychloroquine for autoimmune disease |
| Tetracyclines (tetracycline, doxycycline, minocycline) | Teeth brown discoloration + enamel hypoplasia; bone growth inhibition | After 15–20 wks (calcification begins) | Penicillins, cephalosporins, macrolides |
| Aminoglycosides (gentamicin, tobramycin, amikacin) | Fetal ototoxicity (cochlear hair-cell damage, 8th nerve) — rare but real; nephrotoxicity | 2nd/3rd trimester, high/prolonged dose | Piperacillin-tazobactam, cephalosporins, carbapenems, aztreonam |
| Lithium | Ebstein's anomaly (tricuspid valve displacement) — small absolute risk (~1:1000); neonatal toxicity ("floppy baby", goitre) | 1st trimester (cardiac); term (neonatal) | Antipsychotic, an SSRI (with caution), or ECT for bipolar in pregnancy |
| Certain anaesthetics | Nitrous oxide (folate antagonism, 1st trimester); benzodiazepines (cleft palate — controversial); halogenated agents in high dose (uterine atony) | 1st trimester (N2O, benzos) | Propofol, ketamine, etomidate, fentanyl, volatile at <2 MAC |
| Thalidomide, lenalidomide | Phocomelia / limb reduction defects | 1st trimester | Avoid entirely (myeloma programmes use contraception) |
| Misoprostol (PGE1) | Möbius syndrome (facial palsy), limb defects when used as abortifacient; with ongoing pregnancy | Variable | Avoid in pregnancy (use for induction under obstetric protocol) |
Detail on the four most-tested syndromes. [1]
- Fetal warfarin syndrome. Warfarin crosses the placenta and inhibits fetal vitamin-K-dependent clotting factors and osteocalcin (a bone matrix protein). The classic triad is nasal hypoplasia + stippled epiphyses + distal limb hypoplasia, seen with 6–12 week exposure; later exposure causes CNS abnormalities (Dandy-Walker malformation, agenesis of the corpus callosum, optic atrophy) and fetal/intracranial haemorrhage. Risk is dose-dependent (higher with >5 mg/day). The safe substitute is LMWH/UFH — neither crosses the placenta. For a pregnant woman on warfarin (e.g. a mechanical heart valve), switch to LMWH before conception or as soon as pregnancy is confirmed, with anti-Xa monitoring.[1]
- ACE fetopathy. ACE inhibitors and ARBs reduce fetal glomerular filtration → oligohydramnios → Potter sequence (limb contractures, pulmonary hypoplasia), cranial ossification defects (hypocalvaria), IUGR, and fetal/neonatal death from renal failure. Once considered only a 2nd/3rd-trimester risk, Cooper et al. (NEJM 2006) showed even 1st-trimester exposure roughly doubled major malformation risk — so the modern stance is avoid ACEi/ARB throughout pregnancy. Switch hypertensive patients to labetalol (first-line), methyldopa, hydralazine, or nifedipine.[1]
- Fetal valproate syndrome. Valproate is the most teratogenic antiepileptic: 1st-trimester exposure causes neural tube defects (and cardiac, facial, skeletal anomalies) at ~2–3× baseline rate, and the NEAD trial (Meador 2013) showed the worst cognitive outcome of any AED (mean IQ 6–9 points lower at age 6). Regulators worldwide now restrict valproate in women of childbearing potential. The substitute is levetiracetam (safest AED in pregnancy) or lamotrigine.[1]
- Retinoid embryopathy (isotretinoin). Oral isotretinoin (for severe acne) is a potent teratogen — retinoic acid signalling governs neural-crest and craniofacial development. Exposure causes craniofacial, cardiac (conotruncal), thymic, and CNS defects in ~20–35% of exposed pregnancies. Programmes like iPLEDGE enforce contraception and pregnancy testing before and during therapy. Acitretin (psoriasis) requires contraception for 3 years after stopping (long half-life of metabolite).[1]
Vasopressors in pregnancy — the "treat the mother" principle
The single most important vasopressor concept in obstetric critical care: maternal hypotension kills the fetus faster and more reliably than any vasopressor. Uteroplacental perfusion is not autoregulated — uterine blood flow is directly proportional to uterine arterial pressure minus uterine venous pressure, and falls in proportion to maternal MAP. A few minutes of maternal hypotension → fetal hypoxia, bradycardia, brain injury, death. So the rule is: resuscitate the mother aggressively — do not let hypoperfusion persist out of vasopressor-phobia.[1][1]
Vasopressors in pregnancy — acceptability and rationale
| Agent | Pregnancy status | Rationale / notes |
|---|---|---|
| Noradrenaline (norepinephrine) | SAFE / PREFERRED in ICU | Minimal placental transfer; potent alpha with modest beta — restores maternal MAP and therefore uteroplacental flow. The workhorse ICU vasopressor in pregnancy. Older category-C labels reflect animal data, not proven human harm; modern obstetric anaesthesia/ICU uses it freely. |
| Phenylephrine | SAFE / PREFERRED for spinal hypotension | Pure alpha-1 agonist; first-line for hypotension after spinal anaesthesia for caesarean (PAC study, Ngan Kee 2008 — superior to ephedrine, less fetal acidosis). Short-acting, titratable infusion. |
| Metaraminol | SAFE / ACCEPTABLE | Mixed alpha > beta; commonly used in Australasian obstetric anaesthesia as a phenylephrine alternative; no teratogenic signal at clinical doses. |
| Adrenaline (epinephrine) | SAFE / ACCEPTABLE | Some historical caution (uterine vasoconstriction in animal models) but in human practice adrenaline is used freely in anaphylaxis, cardiac arrest and refractory shock in pregnancy — the benefit of restoring perfusion outweighs theoretical concern. Used in maternal cardiac arrest (ALS algorithm unchanged in pregnancy). |
| Vasopressin | SAFE / ACCEPTABLE | Used in vasodilatory/septic shock refractory to catecholamines; no teratogenic signal; small historical association with uterine contraction is dose/exposure dependent and not seen at shock-resuscitation doses. |
| Dopamine | Acceptable but obsolete | Largely replaced; no specific fetal advantage; renal-dose dopamine debunked. |
| Ephedrine | Acceptable, second-line | Historical first-line for spinal hypotension, now second to phenylephrine (more fetal acidosis / tachyphylaxis). Still used for acute maternal hypotension boluses. |
The exam line you must be able to give: "All commonly used ICU vasopressors — noradrenaline, metaraminol, adrenaline, phenylephrine, vasopressin — are acceptable in pregnancy when the mother is hypotensive. Untreated maternal hypotension causes fetal hypoxia; do not withhold a vasopressor. Noradrenaline is the ICU first-line; phenylephrine is first-line for spinal-anaesthesia hypotension in caesarean section."[1][1]
Vasopressor use in the pregnant ICU patient — a logical sequence
- TREAT THE CAUSE + FLUID-RESPONSIVE FIRST — Identify and correct the underlying shock (haemorrhage, sepsis, PE, anaphylaxis). Give a cautious fluid bolus (250–500 mL crystalloid) if fluid-responsive — but remember pregnancy physiology (low SVR, tendency to pulmonary oedema in pre-eclampsia) — avoid drowning the patient.
- LEFT LATERAL TILT / UTERINE DISPLACEMENT — >20 weeks, manually displace or tilt the gravid uterus off the IVC to relieve aortocaval compression and restore venous return — a 15–30° left tilt can raise BP 10–20 mmHg with no drug at all.
- NORADRENALINE AS FIRST-LINE ICU VASOPRESSOR — Start at 0.05–0.1 mcg/kg/min, titrate to MAP ≥65 mmHg (and maternal lactate clearing, urine output, fetal heart rate if monitored). Do NOT delay for theoretical fetal concern.
- ADD VASOPRESSIN OR ADRENALINE IF REFRACTORY — Septic/vasodilatory shock escalating on noradrenaline: add vasopressin (0.03 U/min) or adrenaline. Maternal perfusion is the priority; fetal monitoring guides delivery timing, not vasopressor choice.
- MONITOR FETAL HEART RATE IF VIABLE (>23–24 WEEKS) — Continuous CTG if available; vasopressors (and maternal shock) can cause fetal decelerations. Decelerations prompt maternal resuscitation and obstetric review for delivery — they do NOT prompt withdrawal of vasopressors.
- CONSIDER DELIVERY IF SHOCK IS OBSTETRIC IN ORIGIN OR FETAL COMPROMISE PERSISTING — Sepsis from chorioamnionitis, severe pre-eclampsia/HELLP, AFLP, amniotic fluid embolism, massive haemorrhage — delivery of the fetus/placenta is often part of the resuscitation. Multidisciplinary decision (ICU, obstetrics, anaesthesia, neonatology).
Induction agents and anaesthesia in pregnancy
For rapid sequence induction and general anaesthesia in pregnancy, no induction agent is a proven human teratogen at clinical doses. The choice is governed by haemodynamics and the obstetric airway, not by teratogenicity.[1]
Induction and neuromuscular agents in pregnancy
| Agent | Pregnancy safety | Practical note |
|---|---|---|
| Propofol | SAFE | Workhorse induction agent; smooth, antiemetic. Avoid prolonged high-dose infusion in late pregnancy only because of the propofol infusion syndrome risk (same as non-pregnant). Crosses placenta but neonate metabolises rapidly. |
| Ketamine | SAFE | Preserves BP/SVR (sympathetic stimulation) — useful in the hypovolaemic/haemorrhaging pregnant patient. Mild uterotonic effect at high dose; transient fetal heart-rate variability changes but no teratogenicity. Sialorrhoea/emergence phenomena. |
| Etomidate | SAFE / acceptable | Haemodynamically neutral — useful in shock. Single-dose adrenal suppression is clinically irrelevant vs. the need for a stable induction. No proven teratogenicity. |
| Thiopental | SAFE | Classic obstetric RSI agent; largely replaced by propofol but still used; uterine relaxant at high dose. |
| Succinylcholine | SAFE | Depolarising relaxant of choice for RSI — rapid onset/offset; pseudocholinesterase metabolism. Slightly prolonged block in pregnancy (lower pseudocholinesterase levels). |
| Rocuronium | SAFE | Non-depolarising alternative when sux contraindicated (1.2 mg/kg for RSI; reversed by sugammadex which itself has reassuring pregnancy data). |
| Volatile agents (sevoflurane, isoflurane, desflurane) | SAFE at <2 MAC | No teratogenicity at clinical concentrations; cause dose-dependent uterine atony at high MAC (use low MAC + oxytocin at caesarean). Nitrous oxide avoided in 1st trimester (folate antagonism) but safe later. |
| Benzodiazepines (midazolam) | CAUTION 1st trimester; acceptable short-term later | Cleft palate signal (controversial); routine RSI does not require a benzodiazepine. |
| Neuraxial (spinal/epidural) | PREFERRED when feasible | Avoids airway (pregnant airway oedema = difficult intubation, ↑aspiration risk); needs platelets >75–80, INR <1.4, no coagulopathy. Spinal hypotension → phenylephrine infusion. |
The pregnant RSI. Pregnancy-specific hazards are physiological, not teratogenic: (1) difficult airway (oedema, engorged mucosa, breast enlargement, short neck — higher failed-intubation rate); (2) aspiration risk (relaxed lower oesophageal sphincter, raised intragastric pressure, delayed gastric emptying in labour — full stomach); (3) rapid desaturation (low functional residual capacity + high oxygen consumption — apnoeic desaturation in <2 min); (4) aortocaval compression (uterus on IVC after 20 weeks — left tilt). The RSI uses pre-oxygenation with 100% O₂ for 3 min, head-up/ramped position, left uterine displacement, cricoid pressure (debatable but traditional), propofol or ketamine, sux or rocuronium 1.2 mg/kg, and a small endotracheal tube (6.0–6.5) with a videolaryngoscope and a senior operator plus a difficult-airway plan.[1]
Lactation
- The MOST ICU drugs the compatible with the breastfeeding (the infant the dose typically under 1 per cent of the maternal dose).[1]
- The AVOID: the chloramphenicol (the bone marrow), the tetracyclines (the high in the milk), the amiodarone (the high the iodine), the lithium (the high in the milk), the radioisotopes.[1]
- The sedatives: the pump and the dump the after the propofol or the fentanyl or the midazolam the boluses; the resume the when the maternal the sedation the clears.[1]
The science of drug transfer into breast milk
Transfer depends on (1) maternal plasma concentration, (2) degree of protein binding (highly bound → less transfer), (3) lipid solubility (fat-soluble drugs concentrate in lipid-rich milk), (4) molecular weight, and (5) oral bioavailability in the infant (drugs destroyed in the infant gut — e.g. insulin, heparin, LMWH, large molecules — are essentially harmless via milk). The useful metric is the Relative Infant Dose (RID) = infant dose via milk (mg/kg/day) ÷ maternal dose (mg/kg/day). A drug is generally considered compatible with breastfeeding if RID <10%.[1]
The definitive reference is LactMed (the US National Library of Medicine's Drugs and Lactation Database, free online) — check it for any unfamiliar drug. Briggs' textbook is the print companion.[1]
ICU drugs in lactation — compatible vs avoid
| Drug / class | Lactation status | Notes |
|---|---|---|
| Penicillins, cephalosporins, macrolides, vancomycin, clindamycin, metronidazole, carbapenems, linezolid, antituberculous therapy | COMPATIBLE | Most antibiotics safe; monitor infant gut (loose stools, thrush) |
| Aminoglycosides (gentamicin) | COMPATIBLE | Poor oral absorption by infant → minimal systemic effect |
| Warfarin, heparin, LMWH, fondaparinux | COMPATIBLE | Highly protein-bound / not orally absorbed → not in milk in active amounts |
| Propofol, fentanyl, morphine, ketamine, midazolam, dexmedetomidine | COMPATIBLE (with caveats) | Pump-and-dump for a few hours after IV boluses/prolonged infusion; resume when maternal sedation cleared |
| Noradrenaline, adrenaline, vasopressin | COMPATIBLE | Rapidly metabolised; negligible oral bioavailability in infant |
| Insulin, metformin, levothyroxine, labetalol, methyldopa, amlodipine, enalapril | COMPATIBLE | Antihypertensives and antidiabetics generally safe (ACEi considered safe in lactation even though contraindicated in pregnancy) |
| Prednisolone, hydrocortisone | COMPATIBLE | Wait 4 h after high-dose IV bolus if concerned (negligible transfer otherwise) |
| Levetiracetam, lamotrigine, carbamazepine | COMPATIBLE | Monitor infant sedation; generally continue breastfeeding |
| Paracetamol, ibuprofen, diclofenac | COMPATIBLE | First-line analgesics in lactation (avoid aspirin and opioids in high dose) |
| Amiodarone | AVOID | High iodine content → infant thyroid dysfunction; long half-life |
| Lithium | AVOID (usually) | High milk levels; infant toxicity (CNS, thyroid). Reassess case-by-case; some authorities permit with monitoring |
| Chloramphenicol, tetracyclines (prolonged), doxycycline (short OK) | AVOID | Bone marrow (chloramphenicol); tooth discoloration (prolonged tetracyclines) |
| Chemotherapy / cytotoxics (cyclophosphamide, methotrexate, doxorubicin, etc.) | AVOID | Cessation of breastfeeding required during and for defined washout periods |
| Radioisotopes (I-131, Tc-99m, Ga-67) | AVOID | Concentrate in milk; interrupt breastfeeding per isotope (I-131: cease permanently; Tc-99m: pump-and-dump 12–24 h) |
| Recreational drugs, alcohol (chronic/high dose), nicotine (smoking) | AVOID / caution | Alcohol in modest amounts compatible if timed after feed; smoking — avoid (SIDS risk); illicit drugs contraindicated |
Practical ICU lactation rules. (1) Default to compatible — most ICU drugs, including vasopressors, heparin/LMWH, propofol/fentanyl infusion, and standard antibiotics, are compatible. (2) Pump and dump for 4–12 h after single IV boluses of propofol, midazolam, or high-dose opioids, and after radiographic contrast or Tc-99m radioisotope studies. (3) Halt breastfeeding for amiodarone, lithium, chemotherapy, and radioisotopes (I-131). (4) Maintain maternal milk supply with regular expression (hand/pump every 3–4 h) even while dumping, so lactation can resume post-ICU. (5) When in doubt, consult LactMed.[1][1]
FlowSteps: the pregnant ICU admission medication review
A 10-point medication review for every pregnant ICU admission
- RECONCILE EVERY DRUG — Allergies, regular meds (especially antihypertensives, anticoagulants, antiepileptics, diabetes therapy, immunosuppression, thyroid replacement, mental-health meds). Mark each as SAFE / CAUTION / CONTRAINDICATED.
- STOP the absolute contraindications — warfarin (switch to LMWH), ACEi/ARB (switch to labetalol/methyldopa), valproate (switch to levetiracetam), isotretinoin/methotrexate/tetracyclines/retinoids, NSAIDs after 20 weeks, DOACs (switch to LMWH), SGLT2i/GLP-1/DPP-4 (switch to insulin).
- SUBSTITUTE with pregnancy-safe equivalents — antibiotics to penicillins/cephalosporins/macrolides; analgesia to paracetamol ± opioids; antihypertensives to labetalol/nifedipine/hydralazine/methyldopa; anticoagulation to LMWH.
- DO NOT UNDER-TREAT THE MOTHER — full-dose sepsis antibiotics (often higher/more frequent dosing), adequate anticoagulation, vasopressors to target MAP ≥65, antiepileptics at therapeutic levels. Maternal survival is the priority.
- CHECK GESTATION AND TIMING WINDOWS — teratogenic risk is concentrated in organogenesis (weeks 3–10); later pregnancy concerns are organ-specific (ACE fetopathy, tetracycline teeth, NSAID ductus). Note the gestation on the chart.
- PRESCRIBE FOLIC ACID (5 mg if high-risk) AND ASPIRIN (75–150 mg if high-risk pre-eclampsia) when appropriate and not contraindicated by bleeding.
- PLAN THROMBOPROPHYLAXIS — pregnancy is a hypercoagulable state; most ICU patients warrant LMWH prophylaxis (mechanical + pharmacological) unless actively bleeding. Switch to UFH infusion 36 h before planned delivery.
- PLAN THE AIRWAY AND RSI — pregnant airway = difficult airway; senior operator, videolaryngoscope, small tube, ramped position, left tilt, aspiration precautions (rapid-sequence). Document a difficult-airway plan.
- INVOLVE THE MULTIDISCIPLINARY TEAM — obstetric medicine/obstetrics, obstetric anaesthesia, pharmacy, neonatology. Decide fetal monitoring strategy (CTG if >23–24 weeks) and the threshold for delivery.
- ADDRESS LACTATION EARLY — if postpartum or likely to deliver, decide whether breastfeeding is the goal; express/pump to maintain supply; flag amiodarone/lithium/chemo/radioisotope as breastfeeding-contraindicated.
TrialCards
PLLR — FDA Pregnancy and Lactation Labelling Rule (2014)
- Design. FDA regulatory rule replacing the 1979 A/B/C/D/X letter categories with structured narrative labelling.
- What changed. New drug labels carry three narrative subsections: 8.1 Pregnancy (risk summary, clinical considerations, data), 8.2 Lactation, 8.3 Females/Males of Reproductive Potential.
- Why. A single letter could not convey trimester-dependence, dose–response, or the difference between "no data" and "known harm".
- Exam relevance. Letters are gone from US inserts but still examined — know both the legacy A–X system AND that PLLR is the current standard.
PAC Study — Ngan Kee (2008): phenylephrine vs ephedrine for spinal hypotension in caesarean section
- Design. RCT of phenylephrine infusion vs ephedrine infusion to maintain maternal BP after spinal anaesthesia for caesarean.
- Result. Phenylephrine (pure alpha-1 agonist) maintained maternal BP with LESS fetal acidosis than ephedrine (which crosses placenta and stimulates fetal β-receptors → metabolic acidosis).
- Bottom line. Phenylephrine is first-line for spinal-anaesthesia hypotension in the obstetric patient; ephedrine is second-line.
Cooper et al. (NEJM 2006): ACE inhibitors in the first trimester
- Design. Cohort study of first-trimester ACE inhibitor exposure vs other antihypertensives vs no antihypertensive.
- Result. First-trimester ACE inhibitor exposure roughly DOUBLED the risk of major congenital malformations (cardiac, CNS) — extending the known 2nd/3rd-trimester ACE fetopathy risk to early pregnancy.
- Bottom line. Avoid ACE inhibitors (and ARBs) throughout pregnancy, not just in 2nd/3rd trimester. Switch hypertensive women of reproductive age to labetalol/methyldopa/nifedipine BEFORE conception.
NEAD Study — Meador (2013): fetal antiepileptic drug exposure and cognition at age 6
- Design. Prospective cohort of children exposed in utero to carbamazepine, lamotrigine, phenytoin, or valproate.
- Result. Valproate produced the lowest IQ at age 6 (6–9 points below the other AEDs); dose-dependent; higher doses worse. Effect persisted after adjusting for maternal IQ.
- Bottom line. Valproate is the worst antiepileptic for fetal cognition and is contraindicated in pregnancy when any alternative exists. Levetiracetam and lamotrigine are preferred.
ASH 2018 guideline — VTE in pregnancy (Bates et al.)
- Design. American Society of Hematology evidence-based guideline on prevention and treatment of venous thromboembolism in pregnancy.
- Recommendations. LMWH over UFH for both treatment and prophylaxis (better safety profile, less osteoporosis, less HIT). Treat acute VTE with weight-based LMWH for the remainder of pregnancy and 6 weeks postpartum (minimum 3 months). Switch to UFH infusion near planned delivery for neuraxial access. DOACs and warfarin avoided in pregnancy (warfarin safe postpartum/lactation).
- Bottom line. LMWH is the anticoagulant of choice in pregnancy — does not cross the placenta; switch from warfarin/DOACs at first pregnancy recognition.
Exam practice — SAQs
SAQ — Safe ICU drugs in pregnancy: the septic, ventilated, anticoagulated pregnant patient
10 minutes · 10 marks
A 31-year-old woman at 26 weeks gestation is admitted to the ICU with septic shock from an obstructed pyelonephritis (ESBL E. coli). She is intubated and ventilated, on noradrenaline 0.25 mcg/kg/min (MAP 62, lactate 4.1), and has a Starr-Edwards mechanical mitral valve (on warfarin, switched to LMWH at the booking visit), essential hypertension (on ramipril, switched to labetalol at booking), and juvenile myoclonic epilepsy (on valproate, transitioned to levetiracetam pre-conception). The fetal heart is viable on CTG. Outline a pregnancy-safe ICU prescribing plan across anticoagulation, antihypertensives, antibiotics, vasopressors, sedation and antiepileptics.
SAQ — Teratogenic drugs to avoid: the polypharmacy patient at the organogenesis window
10 minutes · 10 marks
A 28-year-old woman at 8 weeks gestation (confirmed by a dating scan 2 days ago at the antenatal clinic) is admitted to the ICU after a polypharmacy overdose. She is haemodynamically stable and self-ventilating. Her regular medications, reconciled on admission, are: oral isotretinoin (severe nodulocystic acne), low-dose oral methotrexate 15 mg weekly (psoriasis), doxycycline (acne), lithium (bipolar affective disorder), ramipril (hypertension), and warfarin (a mechanical aortic valve). She also takes valproate as a mood stabiliser. The fetus is at the peak organogenesis window. Classify each drug and outline a safe substitution plan.
Clinical pearls
[1]Red flags
[1] [1] [1]References
- [1]Lapinsky SE, Hébert M Critical illness in pregnancy: part I: an approach to a pregnant patient in the ICU and common obstetric disorders. Chest, 2015.PMID 26020613
- [2]Feghali M, Venkataramanan R, Caritis S The Importance of Clinical Research in Pregnant Women to Inform Prescription Drug Labeling. Journal of Clinical Pharmacology, 2020.PMID 33274508
- [3]Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al Review of Cardiovascular Drugs in Pregnancy. Journal of Women's Health, 2019.PMID 30407107
- [4]Spigset O, Hagg S LactMed Update--An Introduction. Breastfeeding Medicine, 2016.PMID 26859061
- [5]ACOG Committee on Practice Bulletins Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstetrics and Gynecology, 2020.PMID 32443079
- [6]Bates SM, Rajasekhar A, Middeldorp S, et al American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Advances, 2018.PMID 30482767
- [7]Ngan Kee WD, Khaw KS, Ng FF Comparison of phenylephrine infusion regimens for maintaining maternal blood pressure during spinal anaesthesia for Caesarean section. British Journal of Anaesthesia, 2004.PMID 14977792
- [8]Munk-Olsen T, Liu X, Viktorin A, et al Maternal and infant outcomes associated with lithium use in pregnancy: an international collaborative meta-analysis of six cohort studies. Lancet Psychiatry, 2018.PMID 29929874
- [9]Jentink J, Dolk H, Loane MA, et al Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. BMJ, 2010.PMID 21127116
- [10]Meador KJ, Baker GA, Browning N, et al (NEAD Study Group) Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology, 2013.PMID 23352199
- [11]Cooper WO, Hernandez-Diaz S, Arbogast PG, et al Major congenital malformations after first-trimester exposure to ACE inhibitors. New England Journal of Medicine, 2006.PMID 16760444
- [12]Hooton TM, Roberts PL, Stapleton AE, et al Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections: A Randomized Clinical Trial. JAMA Internal Medicine, 2018.PMID 30285042
- [13]Pacheco LD, Saade GR, Hankins GDV SMFM Consult Series #47: Sepsis during pregnancy and the puerperium. American Journal of Obstetrics and Gynecology, 2019.PMID 30684460
- [14]Ito S Drug therapy for breast-feeding women. New England Journal of Medicine, 2000.PMID 10891521